Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: A systematic review and meta-analysis

10Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: To evaluate how efficacy outcomes from real-world data (RWD) can support those from randomized controlled trials (RCTs), in the context of first-line tyrosine kinase inhibitor treatment of metastatic renal cell carcinoma. Patients & methods: PubMed, Ovid, MEDLINE and EMBASE were searched for RCTs and RWD studies with ≥50 adult patients per arm published in 2000-2017. Outcome measures were median progression-free survival, median overall survival and objective response rate. Results: A total of 13 RCTs and 22 RWD studies met eligibility criteria; 31, 28 and 25 studies, respectively, reported median progression-free survival, median overall survival and objective response rate. Summary outcome measures were similar in RWD and RCTs. Conclusion: RWD validates efficacy-based outcomes from RCTs and may provide supportive evidence to inform clinical decisions.

Cite

CITATION STYLE

APA

Moran, M., Nickens, D., Adcock, K., Bennetts, M., Charnley, N., & Fife, K. (2019). Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: A systematic review and meta-analysis. Future Oncology. Future Medicine Ltd. https://doi.org/10.2217/fon-2019-0421

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free